 |
Encouraging results from a new combination treatment for people with very active relapsing-remitting MS (RRMS) are about to be published by a research team at the Walton Centre for Neurology and Neurosurgery in Liverpool, UK.
The team used mitoxantrone (an immunosuppressant drug normally used in cancer) and Glatiramer acetate (Copaxone) in a study of 27 patients with RRMS and reported a significant reduction in relapses and some stabilisation of disability.
To read more, please follow the link below.
Source: UK MS Society
Weblink: click here
|
